Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.

##STR00001##

Disclosed in the present invention are a fused pyridone compound, and a preparation method therefor and a use thereof. Specifically, the present invention discloses a compound of formula (I-B), an optical isomer thereof and a pharmaceutically acceptable salt thereof, and the use of the compound as a KRAS inhibitor.

##STR00001##

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R.sup.1-R.sup.4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X.sub.3 or P2X.sub.2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

##STR00001##

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R.sup.1-R.sup.4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X.sub.3 or P2X.sub.2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

##STR00001##

There are provided a compound of Formula (1) and a labeled biological substance having the compound.

##STR00001##

Z.sup.1 and Z.sup.2 represent a specific 6-membered ring. However, at least one of Z.sup.1 or Z.sup.2 is a benzene ring having a specific substituent at an ortho position with respect to a nitrogen atom to which L.sup.1 or L.sup.2 is bonded, or a specific nitrogen-containing 6-membered ring in which a ring-constituting atom located at the ortho position is a nitrogen atom.

R.sup.1 to R.sup.4, R.sup.11 to R.sup.13, L.sup.1, L.sup.2, and R.sup.21 represents specific groups, and n, α1, α2, and m represent specific numbers.

The compound has at least one structure represented by —(CH.sub.2—CH.sub.2—O).sub.m-R.sup.21 on a heterocyclic ring and has at least one substituent capable of being bonded to a carboxy group or a biological substance at a specific position, and in a case where at least one of Z.sup.1 or Z.sup.2 is the specific nitrogen-containing 6-membered ring, the specific substituents may be bonded to each other to form a ring.

The disclosure provides compounds of Formula (I) ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein W.sup.1, W.sup.2, Y, Z, M, L, C.sup.y, C.sup.z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.2a, R.sup.y, R.sup.z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The disclosure provides compounds of Formula (I) ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein W.sup.1, W.sup.2, Y, Z, M, L, C.sup.y, C.sup.z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.2a, R.sup.y, R.sup.z and the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

A light emitting element that includes a first electrode, a second electrode, and an emission layer between the first electrode and the second electrode is provided. The emission layer includes a polycyclic compound represented by Formula 1. The light emitting element shows a high emission efficiency and long-life characteristics.

##STR00001##